Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imunon, Inc. is conducting a Phase I/II clinical trial titled ‘A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.’ The study aims to assess the safety, dosing, efficacy, and biological activity of IMNN-001 when combined with standard chemotherapy in treating advanced ovarian cancer.
The intervention being tested is IMNN-001, a biological treatment formulated with IL-12 plasmid and PEG-PEI-Cholesterol Lipopolymer, designed to enhance the efficacy of chemotherapy in ovarian cancer patients. It is administered intraperitoneally alongside standard chemotherapy drugs, Carboplatin and Paclitaxel.
This randomized, open-label, multicenter trial uses a parallel intervention model with no masking. The primary purpose is to evaluate treatment efficacy, comparing the combination of IMNN-001 with NACT against NACT alone.
The study began on September 5, 2018, and is currently active but not recruiting. The last update was submitted on August 12, 2025, indicating ongoing progress and data collection.
The clinical trial’s progress could impact Imunon’s stock performance, as positive results may boost investor confidence and market valuation. This study positions Imunon in a competitive landscape where advancements in ovarian cancer treatment are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.